Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
文献类型：期刊论文
| 作者 | Yang, ZiYan2; Wang, Wei1 ; Wang, Xiaojia3; Qin, ZhiQuan2
|
| 刊名 | FRONTIERS IN PHARMACOLOGY
 |
| 出版日期 | 2021-11-01 |
| 卷号 | 12 |
| 关键词 | cardiotoxicity ErbB2 targeting drugs breast cancer therapy |
| DOI | 10.3389/fphar.2021.741451 |
| 通讯作者 | Wang, Xiaojia(wxiaojia0803@163.co) ; Qin, ZhiQuan(qzq66@126.com) |
| 英文摘要 | Breast cancer is the most common form of cancer in women and its incidence has been increasing over the years. Human epidermal growth factor receptor 2 (HER2 or ErbB2) overexpression is responsible for 20 to 25% of invasive breast cancers, and is associated with poor prognosis. HER2-targeted therapy has significantly improved overall survival rates in patients with HER2-positive breast cancer. However, despite the benefits of this therapy, its cardiotoxicity is a major concern, especially when HER2-targeted therapy is used in conjunction with anthracyclines. At present, the mechanism of this cardiotoxicity is not fully understood. It is thought that HER2-targeting drugs inhibit HER2/NRG 1 dimer formation, causing an increase in ROS in the mitochondria of cardiomyocytes and inhibiting the PI3K/Akt and Ras/MAPK pathways, resulting in cell apoptosis. Antioxidants, ACE inhibitors, angiotensin II receptor blockers, beta-blockers, statins and other drugs may have a cardioprotective effect when used with ErbB2-targeting drugs. NT-proBNP can be used to monitor trastuzumab-induced cardiotoxicity during HER2-targeted treatment and may serve as a biological marker for clinical prediction of cardiotoxicity. Measuring NT-proBNP is non-invasive, inexpensive and reproducible, therefore is worthy of the attention of clinicians. The aim of this review is to discuss the potential mechanisms, clinical features, diagnostic strategies, and intervention strategies related to cardiotoxicity of ErbB2-targeting drugs. |
| WOS关键词 | TRASTUZUMAB EMTANSINE ; ADJUVANT THERAPY ; DOUBLE-BLIND ; OPEN-LABEL ; MULTIPLE BIOMARKERS ; CARDIAC BIOMARKERS ; OXIDATIVE STRESS ; RANDOMIZED-TRIAL ; HEART-FAILURE ; CHEMOTHERAPY |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | FRONTIERS MEDIA SA |
| WOS记录号 | WOS:000719852600001 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126484]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Wang, Xiaojia; Qin, ZhiQuan |
| 作者单位 | 1.Bengbu Med Coll, Grad Sch, Bengbu, Peoples R China 2.Zhejiang Prov Peoples Hosp, Dept Oncol Ctr, Oncol, Peoples Hosp,Hangzhou Med Coll, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Dept Breast Med Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, ZiYan,Wang, Wei,Wang, Xiaojia,et al. Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer[J]. FRONTIERS IN PHARMACOLOGY,2021,12. |
| APA | Yang, ZiYan,Wang, Wei,Wang, Xiaojia,&Qin, ZhiQuan.(2021).Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer.FRONTIERS IN PHARMACOLOGY,12. |
| MLA | Yang, ZiYan,et al."Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer".FRONTIERS IN PHARMACOLOGY 12(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。